Citations

We’ve gathered published citations for the past many years so that researchers can easily review at their convenience from among the thousands of published articles, how they might use our products in detail or apply these ideas to their own novel thinking for new research.

Search through, read and share our information rich citations below!

Contact us with any questions.

4724 total record number 96 records this year

To narrow your search, use one or more of the following search menus below.

To search by keyword, you may search by the cell/animal/assay/protein/research or publication
Page 34 out of 34
334 citations found

Treatment of anthrax infection with combination of ciprofloxacin and antibodies to protective antigen of Bacillus anthracis

Karginov VA, Robinson TM, Riemenschneider J, Golding B, Kennedy M, Shiloach J, Alibek K

Product: Anthrax Lethal Factor (LF), Recombinant from B. anthracis

Structure-based Inhibitor Discovery against Adenylyl Cyclase Toxins from Pathogenic Bacteria That Cause Anthrax and Whooping Cough

Soelaiman S, Wei BQ, Bergson P, Lee YS, Shen Y, Mrksich M, Shoichet BK, Tang WJ

Product: Anthrax Protective Antigen (PA), Recombinant from B. anthracis

  • Materials:

    Anthrax protective antigen was purchased from List Biological Laboratory (Campbell, CA), …

    Purification of EF, EF3, CyaA-N, and CaMEF3 and CyaA-N, the catalytic domains of EF and CyaA, respectively, as well as calmodulin were purified as described previously (37,38). To express edema factor that has a hexahistidine tag substituted for its leader peptide (amino acids 133) and can be delivered by anthrax-protective antigen into host cells, a plasmid, pProEx-H6-EF, was constructed as follows. The 3.2-kb EcoRI-XhoI fragment was excised from pSE42 (kindly provided by S. Leppla, National Institutes of Health) and inserted into pBluescript. A NotI site was then introduced at the sequence encoding amino acids 3234 of EF by site-directed mutagenesis, and the mutation was confirmed by DNA sequencing. 

Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor

Scobie HM, Rainey GJ, Bradley KA, Young JA

Product: Anthrax Protective Antigen (PA), Recombinant from B. anthracis

  • PA-Binding Studies:

    PA binding to CHO-R1.1 cells that expressed CMG2489-EGFP or ATR/TEM8 sv2-EGFP was assessed by flow-cytometric analysis; 106 cells of each type were incubated with 50 nM PA (1 h, 4C), washed with PBS, incubated with a polyclonal PA-specific rabbit antiserum (9) (1:500 dilution, 1 h, 4C), washed with PBS again, and then incubated with an allophycocyanin-conjugated anti-rabbit antibody (Molecular Probes; 1:2,000 dilution, 1 h, 4C). ELISAs were performed by binding 0.3 g of PA83 (List Biological Laboratories, Campbell, CA)/100 l of TBS in a well of a MaxiSorp plate (Nalge). Samples were then treated with TBST solution (TBS containing 3% BSA and 0.05% Tween 20), washed with TBST, and incubated with 0300 ng of purified CMG2VWA/I-MycHis/100 l TBST in the absence or presence of 1 mM MgCl2, MnCl2, CaCl2, or ZnCl2. The samples were then washed with TBST and incubated with a horseradish peroxidase-conjugated anti-His antibody (1:2,000 dilution; Santa Cruz Biotechnology). All incubations for ELISAs were performed for 1 h at room temperature. The levels of bound antibody were then measured by using Supersignal ELISA Pico chemiluminescent substrate (Pierce) and a luminometer (Victor V, Wallac).

    Intoxication Assays:

    Cell viability assays (WST-1 assay; Roche Molecular Biochemicals) were performed in triplicate by incubating 5,000 cells of each type for 30 h with 2 1010 M LFN-diptheria toxin A chain (DTA) and varying concentrations of PA (1012 to 108 M; List Biological Laboratories) or no PA (100% viability control). The inhibition assays were performed as above with different amounts of CMG2VWA/I-MycHis (01,000 ng/100 l) added to 109 M PA and 1010 M LFN-DTA before this mixture was added to cells. The IC50 was determined by regression analysis (prism, GraphPad, San Diego).

INTERNALLY QUENCHED FLUOROGENIC SUBSTRATES FOR ANTHRAX LETHAL FACTOR

Shine, N., Eaton, L., Crawford, K.

Product: MAPKKide® Peptide Substrate (DABCYL/FITC) for Anthrax Lethal Factor